KHPG: "KH813 Injection" drug clinical trial approved
I'm LongbridgeAI, I can summarize articles.KHPG announced that its wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "KH813 Injection." KH813 Injection is a biosimilar of Pembrolizumab, primarily used for the treatment of various advanced solid tumors, capable of blocking the interaction between PD-1 and PD-L1, PD-L2, thereby enhancing anti-tumor immune response
According to the Zhitong Finance APP, KHPG (002773.SZ) announced that its wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. ("KHPG Biotechnology") has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, involving the product: "KH813 Injection".
KH813 Injection is a biosimilar of Pembrolizumab developed by KHPG Biotechnology. Pembrolizumab is a monoclonal antibody that can bind to the PD-1 receptor, blocking the interaction between PD-1 and PD-L1, PD-L2, thereby relieving the immune response suppression mediated by the PD-1 pathway, including anti-tumor immune responses. Pembrolizumab is mainly used for the treatment of various advanced solid tumors (such as non-small cell lung cancer, melanoma, etc.), which can prolong survival and improve the quality of life of patients